[1] Zhu J, Tan Z, Hollis-Hansen K, et al. Epidemiological trends in colorectal cancer in China:An ecological study[J]. Dig Dis Sci, 2017,62(1):235-243. [2] Verdier-Pinard P, Wang F, Martello L, et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry[J]. Biochemistry, 2003, 42(18):5349-5357. [3] 权继传,解亦斌,田艳涛. 国际抗癌联盟胃癌TNM分期系统第七版解读[J]. 中华诊断学电子杂志,2014,2(1):59-61. [4] Fife CM, McCarroll JA, Kavallaris M. Movers and shakers:cell cytoskeleton in cancer metastasis[J]. Br J Pharmacol, 2014, 171(24):5507-5523. [5] Klute K, Nackos E, Tasaki S, et al. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy[J]. Onco Targets Ther, 2014, 7:2227-2236. [6] Portyanko A, Kovalev P, Gorgun J, et al. β Ⅲ-tubulin at the invasive margin of colorectal cancer:possible link to invasion[J]. Virchows Arch, 2009, 454(5):541. [7] 曹友红,马平,王福根,等. β-tubulin Ⅲ在胃癌中的表达及临床意义[J]. 新医学,2014(7):444-447. [8] Tsourlakis MC, Weigand P, Grupp K, et al. β Ⅲ-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion[J]. Am J Pathol, 2014, 184(3):609-617. [9] Koh Y, Kim TM, Jeon YK, et al. Class Ⅲ-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma[J]. Ann Oncol, 2009, 20(8):1414-1419. [10] Lebok P, Öztürk M, Heilenk tter U, et al. High levels of class Ⅲ β-tubulin expression are associated with aggressive tumor features in breast cancer[J]. Oncol Lett, 2016, 11(3):1987-1994. [11] Du J, Li B, Fang Y, et al. Overexpression of class Ⅲ β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage Ⅲ ovarian epithelial cancer[J]. BMC Cancer, 2015, 15(1):536-547. [12] Melling N, Tsaklakidis AM, Simon R, et al. β Ⅲ-tubulin overexpression is linked to left-sided tumor localization and nuclear β-catenin expression in colorectal cancer[J]. Cancer Treat Commun, 2015, 6(4):96-102. [13] 杨清海, 陈惠玲, 曾德华,等. 非黏液型肺腺癌中β-Tubulin-Ⅲ作为早期浸润灶标志物的应用[J]. 临床与实验病理学杂志,2016,32(7):753-756. [14] Izutsu N, Maesawa C, Shibazaki M, et al. Epigenetic modification is involved in aberrant expression of class Ⅲ beta-tubulin, TUBB3, in ovarian cancer cells[J]. Int J Oncol, 2008, 32(6):1227-1235. [15] Zou ZQ, Du YY, Sui G, et al. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.[J]. Asian Pac J Cancer Prev, 2015, 16(8):3189-3194. [16] 杨立伟,韩青松,栾艳超,等. 食管鳞癌患者ERCC1、TYMS、TUBB3的表达特征及其与化疗效果的相关性分析[J]. 基因组学与应用生物学, 2016(11):2941-2945. [17] Lu M, Gao J, Wang X, et al. Expressions of thymidylate synthase, thymidine phosphorylase, class Ⅲ β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin[J]. Chin J Cancer Res, 2011, 23(4):288-294. [18] Aldonza MBD, Hong JY, Alinsug MV, et al. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation[J]. Oncotarget, 2016, 7(23):34395-34419. [19] 钟科. TUBB3和TOP2A与晚期乳腺癌患者临床病理特征及与紫杉类联合蒽环类药物治疗疗效的关系[J]. 第三军医大学学报, 2016, 38(14):1659-1663. [20] Ming X, Yi T, Chen WW, et al. Tubb3 regulation by the Erk and Akt signaling pathways:a mechanism involved in the effect of arginine ADP-ribosyltransferase 1(Art1) on apoptosis of colon carcinoma CT26 cells[J]. Tumor Biol, 2016, 37(2):2353-2363. [21] Yang Z, Liu Y, Shi C, et al. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways[J]. Oncol Rep, 2017, 37(2):1011-1019. |